此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ORKA-001 用于斑块状银屑病患者的开放性扩展研究

2026年10月21日 更新者:Oruka Therapeutics, Inc.

一项评估ORKA-001在中度至重度斑块型银屑病参与者中长期安全性、耐受性和有效性的开放标签扩展研究

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

研究概览

地位

招聘中

干预/治疗

详细说明

This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.

研究类型

介入性

注册 (估计的)

240

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Alberta
      • Edmonton、Alberta、加拿大、T5J 3S9
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Edmonton、Alberta、加拿大、T6G 1C3
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • British Columbia
      • Surrey、British Columbia、加拿大、V3R 6A7
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Surrey、British Columbia、加拿大、V3V 0C6
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • New Brunswick
      • Fredericton、New Brunswick、加拿大、E3B IG9
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Ontario
      • Ajax、Ontario、加拿大、L1S7K8
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • London、Ontario、加拿大、N6H 5L5
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Markham、Ontario、加拿大、L3P 1X3
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Peterborough、Ontario、加拿大、K9J 5K2
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Toronto、Ontario、加拿大、M4W 2N4
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Waterloo、Ontario、加拿大、N2J 1C4
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Quebec
      • Montreal、Quebec、加拿大、H2X2V1
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Québec、Quebec、加拿大、G1V4X7
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Arizona
      • Phoenix、Arizona、美国、85032
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Arkansas
      • North Little Rock、Arkansas、美国、72117
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • California
      • Fountain Valley、California、美国、92708
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Los Angeles、California、美国、90045
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Los Angeles、California、美国、90095
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • San Diego、California、美国、92123
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Santa Ana、California、美国、92701
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Santa Monica、California、美国、90403
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Connecticut
      • Cromwell、Connecticut、美国、06416
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Florida
      • Miami、Florida、美国、33126
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Illinois
      • Rolling Meadows、Illinois、美国、60008
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Indiana
      • Plainfield、Indiana、美国、46168
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Kentucky
      • Bowling Green、Kentucky、美国、42104
    • Maryland
      • Rockville、Maryland、美国、20850
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Massachusetts
      • Boston、Massachusetts、美国、02111
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Michigan
      • Detroit、Michigan、美国、48202
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • New York
      • New York、New York、美国、10023
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • New York、New York、美国、10029
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Ohio
      • Cleveland、Ohio、美国、44106
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Mason、Ohio、美国、45040
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Oregon
      • Portland、Oregon、美国、97201
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Portland、Oregon、美国、97210
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Texas
      • Frisco、Texas、美国、75033
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Houston、Texas、美国、77004
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
      • Webster、Texas、美国、77598
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:
    • Virginia
      • Norfolk、Virginia、美国、23502
        • 招聘中
        • Oruka Therapeutics Investigative Site
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Signed informed consent by participants from previous trial choosing to transition into the OLE.
  2. Participants who have successfully completed the preceding trial.
  3. For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
  4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception

Exclusion Criteria:

  1. Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
  2. Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
  3. Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
  4. Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
  5. Participant is pregnant or breastfeeding.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:ORKA-001 Once Yearly (High Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

实验性的:ORKA-001 Once Yearly (Low Dose)

Participants will receive ORKA-001 once a year per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

实验性的:ORKA-001 Twice Yearly

Participants will receive ORKA-001 every 6 months per OLE protocol.

ORKA-001 administered by subcutaneous (SC) injection

无干预:No Drug

Participants will receive no drug until protocol defined PASI response criterion is met.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
大体时间:Day 1 through Week 144

Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.

Day 1 through Week 144

次要结果测量

结果测量
措施说明
大体时间
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
大体时间:Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
大体时间:Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
大体时间:Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
大体时间:Time Frame: Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Time Frame: Day 1 through Week 96
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
大体时间:Day 1 through Week 96

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
大体时间:Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
大体时间:Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
PASI Score Over Time
大体时间:Day 1 through Week 96

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Day 1 through Week 96
IGA Score Over Time
大体时间:Day 1 through Week 96

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Day 1 through Week 96

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年2月23日

初级完成 (估计的)

2030年5月1日

研究完成 (估计的)

2030年7月1日

研究注册日期

首次提交

2026年2月26日

首先提交符合 QC 标准的

2026年2月26日

首次发布 (实际的)

2026年3月4日

研究记录更新

最后更新发布 (实际的)

2026年10月23日

上次提交的符合 QC 标准的更新

2026年10月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • ORKA-001-113

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅